OGN Stock Analysis

Organon & Co (OGN): A Comprehensive StockValueFinder Review

Organon & Co is a healthcare company operating in the drug manufacturing sector. This detailed analysis aims to provide an educational overview of Organon's performance based on the StockValueFinder framework, which evaluates stocks across multiple financial metrics and trends.

Why the StockValueFinder Score Matters The StockValueFinder score for OGN stands at 17%, with a rating of AVOID. The scoring system is designed to help investors identify companies that are financially strong, undervalued, and have favorable market conditions. Given this low score and negative rating, it suggests that Organon & Co may not be an attractive investment opportunity based on the criteria evaluated by StockValueFinder.

EPS Strength and Consistency Earnings per share (EPS) is a critical metric for assessing a company's profitability and financial health. A consistent and growing EPS over time indicates strong management performance and business stability. For Organon & Co, the EPS test was marked as "Did not pass," which means that detailed historical EPS data were not provided in the supplied facts. However, typically, a positive trend in EPS over multiple reporting periods would be desirable.

**Example:** If Company A has an EPS of $2.50 this year and increased from $2.10 last year, it shows better earnings growth compared to Company B with an EPS of $2.40 that decreased from $2.60 last year.

ROIC and Capital Efficiency Return on Invested Capital (ROIC) measures how effectively a company uses its capital to generate profits. A higher ROIC indicates more efficient use of capital, which is generally preferred by investors. Organon & Co's ROIC stands at 1.96%, which falls below the typical threshold of 10% or higher that StockValueFinder prefers.

**Example:** Company X with a ROIC of 15% is using its capital more efficiently than Company Y with a ROIC of 4%. This suggests better management and operational effectiveness in Company X.

Interest Coverage and Financial Safety Interest coverage ratio shows how easily a company can pay the interest on its debt. StockValueFinder prefers an interest coverage ratio of at least 6, indicating that the company has sufficient earnings to cover its interest expenses multiple times over. For Organon & Co, the interest coverage test was marked as "Did not pass," implying that the actual figure is likely below this threshold.

**Example:** A company with an interest coverage ratio of 8 can comfortably pay its debt obligations compared to a company with only 2x coverage, which could indicate financial strain and higher risk.

Debt Payback and Balance Sheet Discipline Debt payback years measure how long it would take for a company to repay all its outstanding debts using current earnings. StockValueFinder prefers companies that can repay their debt within three years or less, indicating strong balance sheet management. Organon & Co's debt payback is 16.04 years, which does not meet this favorable criterion.

**Example:** A company with a debt payback period of 1.5 years is in better financial shape compared to one that needs 7 years to repay its debts, as it suggests lower risk and more efficient capital management.

P/E Ratio and Valuation Discipline The Price-to-Earnings (P/E) ratio compares the market price of a stock with its earnings per share. StockValueFinder generally prefers a P/E ratio below 15 for valuation discipline, suggesting that the company is not overvalued relative to its earnings. Organon & Co's current P/E ratio is 17.63, which does not meet this favorable criterion.

**Example:** A stock with a P/E of 8 might be considered more value-oriented than one with a P/E of 40, assuming the business quality remains sound and consistent.

Moving Average Trend and Entry Timing The moving average trend signal for Organon & Co is "STRONG BUY TREND," indicating that the stock has been performing well over recent periods. However, this does not guarantee future performance and should be used in conjunction with other financial metrics to make informed decisions. The entry signal is marked as "N/A," meaning there are no specific buy or sell recommendations based on current data.

**Example:** A strong moving average trend suggests the stock price has been rising consistently over time, but it does not ensure future gains and should be evaluated alongside other factors like financial health and valuation metrics.

Overall Financial Strengths and Weaknesses Organon & Co's performance across various StockValueFinder tests highlights several weaknesses: - **EPS Consistency:** No detailed EPS data was provided to assess earnings growth. - **ROIC Efficiency:** ROIC of 1.96% is significantly below the preferred threshold, indicating poor capital efficiency. - **Interest Coverage:** Likely below the recommended level of 6x coverage, suggesting potential financial strain. - **Debt Payback:** Debt payback period of 16.04 years exceeds the ideal range, highlighting high debt levels and longer repayment periods. - **P/E Ratio:** P/E ratio of 17.63 is higher than the preferred level, indicating possible overvaluation.

Risks and Limitations The low StockValueFinder score and AVOID rating suggest that Organon & Co may carry significant risks for investors looking to build a strong portfolio based on financial metrics alone. Potential risks include poor earnings performance, inefficient capital use, high debt levels, and potentially inflated stock valuation.

Investors should consider these factors alongside broader market conditions, industry trends, and other qualitative assessments before making investment decisions.

Educational Conclusion This review provides an in-depth look at Organon & Co's financial metrics through the StockValueFinder framework. By examining EPS consistency, ROIC, interest coverage, debt payback, P/E ratio, and moving average trend signals, investors can better understand the company’s strengths and weaknesses. However, it is crucial to remember that this analysis serves as an educational tool rather than a definitive buy or sell recommendation.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings